We develop tailored decision intelligence by seeing science and technology, intellectual property, and competitive markets as one operating environment — understanding where they reinforce, constrain, or contradict one another.
The substantive work is where the three domains disagree — where the construct design quietly narrows freedom to operate, where the differentiation claim outruns what the IP defends, where the milestone that looked like progress does not move the number an investor prices.
Most advice arrives siloed. Scientists advise on science, attorneys on patents, consultants on strategy. The disagreements between them are nobody's explicit responsibility — and that is exactly where they compound. Cross-domain is not a style of thinking we happen to prefer; it is the only vantage point from which those disagreements are visible at all.
Where does the science hold at molecular resolution — and where does it depend on assumptions unlikely to survive scale-up, a cell-line change, or regulatory scrutiny?
The scientific reading establishes the boundaries within which the other two domains operate.
Patent landscapes, freedom-to-operate, and strategic positioning — read alongside the technical architecture and commercial claims they must ultimately support.
Does the science support the differentiation? Does the IP defend it? Does the resulting position survive investor or partner scrutiny?
I am Dr Michal Legiewicz, I founded Photon Fusion Ltd because the most damaging failures in platform biotechnology are rarely failures of science, or of strategy, taken alone. They happen at the interfaces between technical design, IP architecture, and commercial positioning — interfaces that conventional advisory structures leave unowned. Scientific advisors assess the biology; patent attorneys assess claim scope; commercial consultants assess market strategy — and none of them is mandated to check whether those three assessments actually agree with each other. That gap is where platform value most often erodes.
My background sits across all three domains. Over two decades in nucleic acid science and technology took me from bench research at the NIH and Yale, through platform development at the University of Warwick and in UK biotech (Touchlight Genetics), to inventor-level patent work on DNA technologies. That combination of first-principles science, practitioner-level patent literacy, and commercial fluency is what catching interface failures actually requires, and it's an unusual one to find in a single advisor.
I work directly with founders, CSOs, and investors who want that kind of gap surfaced before it becomes a diligence finding — someone who can read the molecular biology at first principles, interpret a patent claim with practitioner-level judgment, and assess whether the resulting platform is a durable competitive asset or an inherited liability that simply hasn't come due yet.
My core expertise embraces nucleic acid biochemistry and biology, and its platform applications. This spans gene synthesis and vector design, gene editing and targeted delivery, DNA and mRNA therapeutics, and the emerging frontier where nucleic acid value is migrating next. Some of these areas I practise directly; others I monitor continuously because they shape the IP and commercial landscape in which my clients operate. The distinction matters, and the sections below make it explicit.
Gene design and synthesis, expression systems, construct engineering for manufacturability, and full-stack architecture of synthetic and enzymatic DNA platforms. The foundational layer on which all downstream applications depend, and where architectural decisions quietly determine what remains possible at manufacturing scale.
AAV vector design and non-viral targeted delivery platforms — the domain in which I have contributed directly as a researcher and named inventor. Platform decisions at this layer cascade into manufacturing, IP, and regulatory requirements, which is why the three-map reading is most consequential here.
Nucleic acid aptamer selection (SELEX), structural characterisation, and applications. A field where novel molecular structure intersects with IP opportunities and commercial territory that remain genuinely underexplored.
DNA and RNA nanotechnology, programmable nanostructures, and nucleic acid-based materials. Emerging platforms in which early IP and architectural decisions set long-term positioning.
DNA data storage, and molecular computing. Fields I track continuously because they indicate where nucleic acid IP and platform value are migrating next, even where they are not yet where I practise.
This is one vertex of three. It is the one that takes twenty years to acquire and cannot be read from a database.
It runs on two instruments, both built in-house, both documented. STMC answers where do we actually stand. Path Painter answers which moves stay open, and for how long. STMC's mapped terrain is Path Painter's input; Path Painter's committed route becomes what STMC then monitors. They are a closed loop, not two reports — which is why this is the one place on the site a two-card layout is correct.
Where you actually stand. STMC integrates the situation distiller, Battle Damage Assessment, Intelligence Preparation of the Battlefield, and a reoriented Wardley map into a single reading of a platform's strategic terrain: what is knowable, what is evolving, and what a competitor is about to do about it. Output: a binding constraint, and a five-node dependency map across technology, IP, partner, investor, and market.
Explore STMCWhich moves stay open, and which close if you wait. Path Painter reads STMC's terrain, generates genuinely distinct candidate routes through it, and stress-tests each one structurally — dependency coupling, self-reinforcing commitments, one-way doors, and a pre-mortem that can send a route back for revision. Output: one committed route, and a signed record of exactly what committing to it forecloses.
Explore Path PainterMethod is what we read. This is how we work. Engagements are structured to match the depth and continuity that each mandate requires. From embedded fractional leadership to discrete advisory sessions, the through-line is the same: substantive thinking that produces something worth having.
The deepest form of engagement. Photon Fusion Principal Advisor holds a defined fractional role — typically CTO or CSO — within the client's leadership structure, operating at approximately 20% of working time. This is not a consultancy arrangement wearing an operational title: it is a genuine strategic presence, with the access and continuity that genuine presence requires.
Platform understanding is built iteratively. By month three, the advisor knows the technology well enough to have opinions that matter — on IP architecture, platform positioning, investor narrative, and where the scientific programme and the commercial strategy are in tension.
A bounded engagement with a specific objective and a written deliverable. Typical projects include IP landscape review and whitespace mapping, platform technical assessment, competitive intelligence synthesis, or preparation for a fundraise or licensing discussion.
Scope is defined in a Statement of Work before commencement. Requests outside that scope are identified as such and quoted separately — not absorbed silently. The deliverable is written and stands on its own: not a presentation designed to generate the next meeting, but a document designed to be used.
One-off advisory sessions, expert calls, due diligence reviews, or advisory board participation. No fixed term, no operational involvement. Minimum booking of half a day ensures that any session produces something worth having rather than an introductory conversation dressed as advice.
This tier is also the natural entry point for a relationship that may evolve. Many Tier 1 and Tier 2 engagements begin with a Tier 3 conversation — a chance to assess fit before either party commits to something deeper.
Essays on where platform biotechnology actually fails, and the frameworks for navigating it — from classifying the problem, through triangulating siloed expertise, to the two instruments that turn a cross-domain reading into a committed route.
Photon Fusion engages selectively, prioritising mandates where integrated scientific and strategic perspective can have the most decisive impact. If you are building a biotechnology platform and approaching decisions at which the scientific, IP, and commercial dimensions intersect, I would welcome hearing from you.